EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

Clare J Rowntree, Amy A Kirkwood iD, Nadine Farah, Emma Lawrie, David I Marks, Andrew K McMillan, Tobias F Menne iD, Anthony V Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z Alapi und 3 weitere

HemaSphere · 2026-10 · 10 (10)

DOI: 10.1002/hem3.70480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 01.10.2026. Verfasst von Clare J Rowntree und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cardiff and Vale UHB Cardiff United Kingdom. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Rosetrees Trust, Great Ormond Street Hospital Charity.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m 2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS). From 2011 to 2018, 143 patients were randomly assigned to SOC ( N = 75) or SOC + nelarabine ( N = 68). There was no significant difference in EFS between the treatment groups; HR 0.86 (95% CI 0.52–1.43) P = 0.57, EFS: 58.2% SOC versus 62.7% SOC + nelarabine. The severe adverse events and nonrelapse mortality rates did not differ between the arms; in particular, there was no difference in grade 3–4 neurotoxicity. The 3‐year cumulative incidence of relapse was 31% in the SOC arm versus 28.9% in the SOC+ nelarabine arm. Forty of 44 relapses (90.9%) occurred within 2 years of randomization; the median survival postrelapse was 5.7 months, with no difference by arm. Diagnostic samples were analyzed for level of differentiation arrest by analysis of the TCRg locus to detect the most immature cases through absence of biallelic TCRg deletion (ABD). There was a trend toward more relapses with ABD (37.3%) versus no ABD (19.5%), P = 0.066. Diagnostic samples ( N = 133) were analyzed for mutations in NOTCH1, FBXW7, NRAS, KRAS, and PTEN , with no significant differences in CR rates or survival in patients with wild‐type (WT) NOTCH1 or FBXW7 . The 12 patients with NRAS mutations had significantly inferior CR and EFS compared to patients with wild‐type NRAS .

Autor:innen und Institutionen

  • Cardiff and Vale UHB Cardiff United Kingdom.
  • CRUK and UCL Cancer Trial Centre, Cancer Institute UCL London United Kingdom.
  • UCL Cancer Institute London United Kingdom.
  • United Bristol Healthcare Trust Bristol United Kingdom.
  • Centre for Clinical Haematology Nottingham City Hospital Nottingham United Kingdom.
  • Newcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne United Kingdom.

ORCID-Profile: Amy A Kirkwood, Tobias F Menne, Adele K Fielding

Förderung

  • Cancer Research UK
  • Rosetrees Trust
  • Great Ormond Street Hospital Charity

Zitieren

APA

Rowntree, C. J., Kirkwood, A. A., Farah, N., Lawrie, E., Marks, D. I., McMillan, A. K., Menne, T. F., Moorman, A. V., Patel, B., Patrick, P., Smith, P., Alapi, K. Z., Wang, L., Mansour, M. R., & Fielding, A. K. (2026). One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70480

Vancouver

Rowntree CJ, Kirkwood AA, Farah N, Lawrie E, Marks DI, McMillan AK, et al. One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial. HemaSphere. 2026;10(10). doi:10.1002/hem3.70480

BibTeX
@article{Rowntree2026,
  author = {Rowntree, Clare J and Kirkwood, Amy A and Farah, Nadine and Lawrie, Emma and Marks, David I and McMillan, Andrew K and Menne, Tobias F and Moorman, Anthony V and Patel, Bela and Patrick, Pip and Smith, Paul and Alapi, Krisztina Z and Wang, Lingyi and Mansour, Marc R and Fielding, Adele K},
  title = {One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {10},
  doi = {10.1002/hem3.70480}
}
Kostenlos starten →